Praxis Precision Medicines, Inc. - COMMON STOCK (PRAX)

CUSIP: 74006W207

Q3 2024 13F Holders as of 30 Sep 2024

Holder snapshot 7 signals
Share change
+427,761
Put/Call ratio
81%
SEC-reported price per share
$57.54
Number of holders
132
Value change
+$44,014,289
Number of buys
71
Open additional details 1 more signal available
Number of sells
58
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
27,889,438

Security key

74006W207

Report period

Q3 2024

Institutions

132

Top holders

10

Ownership snapshot

Top reported holders of PRAX - Praxis Precision Medicines, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Clarus Lifesciences III, ...
Disclosed value leader
Clarus Lifesciences III, ...
Comparable rows
0/15
Latest evidence
30 Jun 2024
3/4/5 13F Highest disclosed value: $123,282,606 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Clarus Lifesciences III, L.P. has the largest disclosed position value at $123.28M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Clarus Lifesciences III, L.P.'s linked filing trail.
Disclosed position value Top 5
Clarus Lifesciences III, L.P. $123.28M
BlackRock Finance, Inc. $53.52M
RA CAPITAL MANAGEMENT, L.P. $51.1M
ADAGE CAPITAL PARTNERS GP, L.L.C. $46.91M
Point72 Asset Management, L.P. $43.5M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Clarus Lifesciences III, L.P.
3/4/5
10%+ Owner
—
denominator unverified
$123,282,606
4,894,109 shares
— 12 May 2021
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$53,519,840
1,294,000 shares
— 30 Jun 2024
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$51,104,375
1,235,599 shares
— 30 Jun 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
13F
—
denominator unverified
$46,905,673
1,134,083 shares
— 30 Jun 2024
Point72 Asset Management, L.P.
13F
Company
13F
—
denominator unverified
$43,498,353
1,051,701 shares
— 30 Jun 2024
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$40,414,717
977,145 shares
— 30 Jun 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
132
Shares
18,868,572
Rows available
132
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders
113
Q3 2024 holders
132
Holder diff
19
Investor Q2 2024 Shares Q3 2024 Shares Share Diff Share Chg % Q2 2024 value Q3 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .